Colorectal cancer is the second-leading cause of cancer death in the United States among men and women combined. Refinements in screening, staging, and treatment strategies have improved survival from this disease, with over 65% of patients diagnosed with colorectal cancer surviving over 5 years after diagnosis. In the prognosis of colorectal cancer, clinicopathological factors are important. However, modifiable prognostic factors are emerging as significant contributors to cancer outcomes, including obesity and obesity-related inflammation and metabolic conditions.
Methods:
This report reviews the literature on obesity and obesity-related inflammation and metabolic disturbances and colorectal cancer outcomes (recurrence, disease-free survival, and/or mortality). A PubMed search was conducted of all English-language papers published between August 2003 and 2009 and cited in MEDLINE.
Results:
Primary research papers were reviewed for colorectal cancer outcomes related to obesity, inflammation, or metabolic conditions. An association between body size and colorectal cancer recurrence and possibly survival was found; however, reports have been inconsistent. These inconsistent findings may be due to the complex interaction between adiposity, physical inactivity, and dietary intake. Circulating prognostic markers such as C-reactive protein, insulin-like growth factor, and insulin, alone or in combination, have been associated with prognosis in observational studies and should be evaluated in randomized trials and considered for incorporation into surveillance.
Conclusions:
The literature suggests that obesity and obesity-related inflammation and metabolic conditions contribute to the prognosis of colorectal cancer; however, comprehensive large scale trials are needed. Interventions to reduce weight and control inflammation and metabolic conditions, such as diabetes, need to be evaluated and rapidly translated to behavior guidelines for patients.
HornerM.J., RiesL.A.G., KrapchoM.. eds. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute.Bethesda, MD.http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009. Accessed October 1, 2009.
3.
HewittM., GreenfieldS., StovallE., eds. From Cancer Patient to Cancer Survivor: Lost in Transition.Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council. Washington, DC: The National Academies Press;2005.
4.
WaltherA., JohnstoneE., SwantonC.. Genetic prognostic and predictive markers in colorectal cancer.Nat Rev Cancer.2009; 9(7): 489–499.
5.
Nutrition and Physical Activity Guidelines for Cancer Survivors After Treatment. AICR's Guidelines for Cancer Survivors 2009: American Institute for Cancer Research2006. http://www.aicr.org. Accessed on October 5, 2009.
6.
HjartåkerA., LangsethH., WeiderpassE.. Obesity and diabetes epidemics: cancer repercussions.Adv Exp Med Biol.2008; 630: 72–93.
7.
MeyerhardtJ.A., CatalanoP.J., HallerD.G.. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.Cancer.2003; 98(3): 484–495.
8.
ReevesG.K., PirieK., BeralV.. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study.BMJ.2007; 335(7630): 1134.
9.
MeyerhardtJ.A., TepperJ.E., NiedzwieckiD.. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.J Clin Oncol.2004; 22(4): 648–657.
10.
DignamJ.J., PoliteB.N., YothersG.. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.J Natl Cancer Inst.2006; 98(22): 1647–1654.
11.
MeyerhardtJ.A., NiedzwieckiD., HollisD.. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.J Clin Oncol.2008; 26(25): 4109–4115.
12.
ParkS.M., LimM.K., JungK.W.. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study.J Clin Oncol.2007; 25(30): 4835–4843.
13.
ParkS.M., LimM.K., ShinS.A.. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study.J Clin Oncol.2006; 24(31): 5017–5024.
14.
MoonH.G., JuY.T., JeongC.Y.. Visceral obesity may affect oncologic outcome in patients with colorectal cancer.Ann Surg Oncol.2008; 15(7): 1918–1922.
15.
HaydonA.M., MacinnisR.J., EnglishD.R.. Effect of physical activity and body size on survival after diagnosis with colorectal cancer.Gut.2006; 55(1): 62–67.
16.
HaydonA.M., MacinnisR.J., EnglishD.R.. Physical activity, insulinlike growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer.Gut.2006; 55(5): 689–694.
17.
HawkesA.L., PakenhamK.I., CourneyaK.S.. A randomised controlled trial of a tele-based lifestyle intervention for colorectal cancer survivors (‘CanChange’): study protocol.BMC Cancer.2009; 9: 286.
18.
MeyerhardtJ.A., NiedzwieckiD., HollisD.. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.JAMA.2007; 298(7): 754–764.
19.
MeyerhardtJ.A., SloanJ.A., SargentD.J.. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer.Cancer Epidemiol Biomarkers Prev.2005; 14(6): 1402–1410.
20.
LynchB.M., CerinE., OwenN.. Prospective relationships of physical activity with quality of life among colorectal cancer survivors.J Clin Oncol.2008; 26(27): 4480–4487.
21.
GutierrezD.A., PuglisiM.J., HastyA.H.. Impact of increased adipose tissue mass on inflammation, insulin resistance, and dyslipidemia.Curr Diab Rep.2009; 9(1): 26–32.
BastardJ.P., MaachiM., LagathuC.. Recent advances in the relationship between obesity, inflammation, and insulin resistance.Eur Cytokine Netw.2006; 17(1): 4–12.
OhshimaH., TatemichiM., SawaT.. Chemical basis of inflammation-induced carcinogenesis.Arch Biochem Biophys.2003; 417(1): 3–11.
26.
KumorA., DanielP., PietruczukM.. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients.Int J Colorectal Dis.2009; 24(3): 275–281.
27.
McMillanD.C., CannaK., McArdleC.S.. Systemic inflammatory response predicts survival following curative resection of colorectal cancer.Br J Surg.2003; 90(2): 215–219.
28.
MikiC., KonishiN., OjimaE.. C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma.Dig Dis Sci.2004; 49(6): 970–976.
29.
CrozierJ.E., McKeeR.F., McArdleC.S.. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer.Br J Cancer.2006; 94(12): 1833–1836.
30.
IshizukaM., NagataH., TakagiK.. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer.Ann Surg.2007; 246(6): 1047–1051.
31.
CrozierJ.E., McKeeR.F., McArdleC.S.. Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer.Br J Surg.2007; 94(8): 1028–1032.
32.
IshizukaM., KitaJ., ShimodaM.. Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer.J Surg Oncol.2009; 100(1): 38–42.
33.
ForrestL.M., McMillanD.C., McArdleC.S.. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer.Br J Cancer.2003; 89(6): 1028–1030.
34.
GlenP., JamiesonN.B., McMillanD.C.. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer.Pancreatology.2006; 6(5): 450–453.
35.
Al MurriA.M., BartlettJ.M., CanneyP.A.. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer.Br J Cancer.2006; 94(2): 227–230.
36.
CrumleyA.B., McMillanD.C., McKernanM.. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer.Br J Cancer.2006; 94(5): 637–641.
37.
McMillanD.C., CrozierJ.E., CannaK.. Evaluation of an inflammation based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer.Int J Colorectal Dis.2007; 22(8): 881–886.
38.
LeitchE.F., ChakrabartiM., CrozierJ.E.. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer.Br J Cancer.2007; 97(9): 1266–1270.
39.
FujitaT.. Influence of preoperative inflammation on outcomes of colorectal cancer surgery.Ann Surg.2008; 247(6): 1084–105; author reply 1085-1086.
40.
ChanA.T., OginoS., FuchsC.S.. Aspirin use and survival after diagnosis of colorectal cancer.JAMA.2009; 302(6): 649–658.
41.
BardiaA., EbbertJ.O., VierkantR.A.. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality.J Natl Cancer Inst.2007; 99(11): 881–889.
42.
BlairC.K., SweeneyC., AndersonK.E.. NSAID use and survival after breast cancer diagnosis in postmenopausal women.Breast Cancer Res Treat.2007; 101(2): 191–197.
43.
KwanM.L., HabelL.A., SlatteryM.L.. NSAIDs and breast cancer recurrence in a prospective cohort study.Cancer Causes Control.2007; 18(6): 613–620.
44.
PierceB.L., Ballard-BarbashR., BernsteinL.. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients.J Clin Oncol.2009; 27(21): 3437–3444.
45.
GrauM.V., BaronJ.A., LangholzB.. Effect of NSAIDs on the recurrence of nonmelanoma skin cancer.Int J Cancer.2006; 119(3): 682–686.
46.
CornierM.A., DabeleaD., HernandezT.L.. The metabolic syndrome.Endocr Rev.2008; 29(7): 777–822.
47.
LarssonS.C., OrsiniN., WolkA.. Diabetes mellitus and risk of colorectal cancer: a meta-analysis.J Natl Cancer Inst.2005; 97(22): 1679–1687.
48.
CaudleA.S., KimH.J., TepperJ.E.. Diabetes mellitus affects response to neoadjuvant chemoradiotherapy in the management of rectal cancer.Ann Surg Oncol.2008; 15(7): 1931–1936.
49.
JullumstrøE., KollindM., LydersenS.. Diabetes mellitus and outcomes of colorectal cancer.Acta Oncol.2009; 48(3): 361–367.
50.
MohanS., BaylinkD.J.. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms.J Endocrinol.2002; 175(1): 19–31.
51.
PollakM.. Insulin and insulin-like growth factor signalling in neoplasia.Nat Rev Cancer.2008; 8(12): 915–928.
52.
WolpinB.M., MeyerhardtJ.A., ChanA.T.. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer.J Clin Oncol.2009; 27(2): 176–185.
53.
FuchsC.S., GoldbergR.M., SargentD.J.. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741.Clin Cancer Res.2008; 14(24): 8263–8269.
54.
JiangY., KimchiE.T., Staveley-O'CarrollK.F.. Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer.Cancer.2009; 115(16): 3609–3617.
55.
LynchB.M., CerinE., NewmanB.. Physical activity, activity change, and their correlates in a population-based sample of colorectal cancer survivors.Ann Behav Med.2007; 34(2): 135–143.
56.
HawkesA.L., GollschewskiS., LynchB.M.. A telephone-delivered lifestyle intervention for colorectal cancer survivors ‘CanChange’: pilot study.Psychooncology.2009; 18(4): 449–455.
57.
Ballard-BarbashR., HunsbergerS., AlciatiM.H.. Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations.J Natl Cancer Inst.2009; 101(9): 630–643.
58.
BasergaR.. Customizing the targeting of IGF-1 receptor.Future Oncol.2009; 5(1): 43–50.
59.
ZakikhaniM., DowlingR.J., SonenbergN.. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase.Cancer Prev Res (Phila Pa).2008; 1(5): 369–375.
60.
CampbellK.L., CampbellP.T., UlrichC.M.. No reduction in C-reactive protein following a 12-month randomized controlled trial of exercise in men and women.Cancer Epidemiol Biomarkers Prev.2008; 17(7): 1714–1718.
